Welcome to our dedicated page for PRF Technologies news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PRF Technologies stock.
PRF Technologies Ltd. reports developments across clinical-stage specialty pharmaceuticals and AI-driven solar analytics. The company focuses on reformulating established therapeutics for post-operative pain management and, through majority-owned LayerBio, is developing OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract pain and inflammation.
PRF news also covers the company’s DeepSolar business unit, which develops AI-driven digital asset management, forecasting, performance monitoring, and technical due diligence tools for utility-scale solar plants. Recurring updates include ocular drug-delivery regulatory milestones, preclinical and clinical safety data, patent activity, SaaS deployments, commercial collaborations, capital actions, and governance changes.
PainReform Ltd. (NasdaqCM:PRFX) has announced the pricing of its initial public offering (IPO) involving 2,500,000 units at $8.00 per unit. Each unit includes one Ordinary Share and one Warrant. The offering aims to raise approximately $20.0 million in gross proceeds, and it is expected to close on September 3, 2020. The Company’s shares will start trading on the Nasdaq Capital Market under the symbol PRFX on September 1, 2020. The Company has provided an option for underwriters to purchase an additional 375,000 shares.